Posted by Michael Wonder on 25 Sep 2020
Innova Therapeutics receives rare paediatric disease designation from the FDA for IVT-8086 for the treatment of osteosarcoma
24 September 2020 - Innova Therapeutics Inc., a biopharmaceutical company committed to developing innovative cancer therapies for patients who have inadequate treatment options, today announced that the FDA has granted rare paediatric disease designation for IVT-8086 for the treatment of osteosarcoma.
IVT-8086 is a humanised monoclonal antibody with high affinity to a novel anticancer target, secreted frizzled-related protein 2.
